Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 1 | 4 | 1 | 6 |
Fibrosis | D005355 | — | — | — | — | — | 3 | — | 3 |
Covid-19 | D000086382 | — | U07.1 | — | 1 | — | 1 | — | 2 |
Hidradenitis suppurativa | D017497 | — | L73.2 | — | — | — | 1 | — | 1 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 1 | — | 1 |
Hyperkalemia | D006947 | — | E87.5 | — | — | — | 1 | — | 1 |
Ascites | D001201 | — | R18 | — | — | — | 1 | — | 1 |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | 1 | — | 1 |
Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | 1 | — | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 2 | — | — | 2 |
Infarction | D007238 | EFO_0009463 | — | — | — | 2 | — | — | 2 |
St elevation myocardial infarction | D000072657 | — | — | — | — | 1 | — | — | 1 |
Reperfusion injury | D015427 | — | — | — | — | 1 | — | — | 1 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | — | — | 1 |
Genetic predisposition to disease | D020022 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | 1 | 2 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | — | 1 |
Newborn respiratory distress syndrome | D012127 | — | P22 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
Gender dysphoria | D000068116 | — | F64 | 1 | — | — | — | — | 1 |
Melanosis | D008548 | EFO_0003963 | L81.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
Proteinuria | D011507 | — | R80 | — | — | — | — | 1 | 1 |
Drug common name | Canrenoate potassium |
INN | potassium canrenoate |
Description | Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), also known as aldadiene kalium, the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group. Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@]2(O)CCC(=O)[O-].[K+] |
PDB | — |
CAS-ID | 2181-04-6 |
RxCUI | — |
ChEMBL ID | CHEMBL1371200 |
ChEBI ID | — |
PubChem CID | 23671691 |
DrugBank | DB09015 |
UNII ID | M671F9NLEA (ChemIDplus, GSRS) |